Metabolic and neurological complications of second-generation antipsychotic use in children: a systematic review and meta-analysis of randomized controlled trials.

@article{Pringsheim2011MetabolicAN,
  title={Metabolic and neurological complications of second-generation antipsychotic use in children: a systematic review and meta-analysis of randomized controlled trials.},
  author={Tamara Pringsheim and Darren K M Lam and Heidi Ching and Scott B Patten},
  journal={Drug safety},
  year={2011},
  volume={34 8},
  pages={651-68}
}
BACKGROUND Available evidence indicates that the use of antipsychotics, especially second-generation antipsychotics (SGAs), for children with mental health disorders has increased dramatically. Given the demonstrated metabolic and neurological adverse effects seen in adult patients on these medications, detailed evaluation of the risk for these adverse effects in children is appropriate. OBJECTIVE The aim of the study was to assess the evidence for specific metabolic and neurological adverse… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 36 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 50 references

Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial.

Journal of the American Academy of Child and Adolescent Psychiatry • 2009
View 4 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…